Medicine Overview of Trastunix 440mg/20ml Injection
Trastunix 440 is used in the treatment of breast and stomach cancer. It works by killing the cancer cells by inhibiting HER2 (human epidermal growth factor receptor protein).
Trastunix 440 is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
The most common side effects of this medicine include nausea, headache, rash, insomnia, and infection. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels. You must have to inform your doctor if you experience breathlessness, cough, shivering, swelling of legs and arm.
Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.
- Breast cancer
- Stomach cancer
- Anemia (low number of red blood cells)
- Chills
- Common cold
- Cough
- Decreased blood cells (red cells, white cells, and platelets)
- Diarrhea
- Fatigue
- Fever
- Headache
- Heart failure
- Infection
- Insomnia (difficulty in sleeping)
- Mucosal inflammation
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Taste change
- Upper respiratory tract infection
- Weight loss
-
It is given as an injection into your vein or under the skin, usually over 1 hour.
-
Use effective contraception method to prevent pregnancy while taking this medicine and for 7 months after you stop the treatment.
-
Your doctor will monitor your heart regularly while taking this medicine. Inform your doctor if you notice symptoms such as breathlessness, cough, shivering, swelling of legs and arm.
-
Inform your doctor if you are pregnant, planning pregnancy or breastfeeding.
IV Administration
Not for IV push or bolus administration
Administer initial IV infusion over 90 min
Subsequent weekly IV infusions may be administered over 30 min if prior infusions are well tolerated
Intravenous
Breast Cancer
Adjuvant treatment
Indicated for adjuvant treatment of HER-2 overexpressing breast cancer
Administer during and following paclitaxel, docetaxel, or docetaxel/carboplatin
4 mg/kg IV over 90 minutes, THEN
2 mg/kg IV over 30 minutes qWeek during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel/carboplatin)
One week following the last weekly dose administer at 6 mg/kg as an IV infusion over 30?90 min every three weeks
As single agent within three wk following completion of multi-modality, anthracycline based chemotherapy regimens: Initial dose at 8 mg/kg as an IV infusion over 90 min; subsequent doses at 6 mg/kg as an IV infusion over 30?90 min every three wks
Extending adjuvant treatment beyond one year not recommended
Metastatic breast cancer
Treat as a single agent or in combination with paclitaxel
4 mg/kg IV over 90 minutes, THEN
2 mg/kg IV over 30 minutes qWeek
Gastric Cancer
Indicated for treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
Administered in combination with cisplatin and capecitabine or 5-fluorouracil who have not received prior treatment for metastatic disease
First cycle: 8 mg/kg IV; infuse IV over 90 min
Subsequent cycles: 6 mg/kg IV q3wk; infuse IV over 30-90 min
Continue q3week cycles until disease progression
Safety and efficacy not established
Patient w/ pre-existing CV and pulmonary disease; extensive pulmonary tumour involvement. Pregnancy and lactation. Monitoring Parameters Monitor cardiac function prior and during treatment.
Lactation: not known if excreted in breast milk, discontinue nursing during treatment and for 6 months after last dose
>10%
Pain (47%),Asthenia (42%),Fever (36%),Nausea (33%),Chills (32%),Cough (26%),Headache (26%),Diarrhea (25%),Vomiting (23%),Abdominal pain (22%),Back pain (22%),Dyspnea (22%),Infection (20%),Rash (18%),Anorexia (14%),Insomnia (14%),Dizziness (13%)
1-10%
Flu-like syndrome (10%),Peripheral edema (10%),CHF (7%),Depression (6%),Tachycardia (5%),UTI (5%),Anemia (4%),Hypersensitivity (3%),Leukopenia (3%)
Potentially Fatal: Severe hypersensitivity (anaphylaxis) and infusion reactions; pulmonary events e.g. acute respiratory distress syndrome; cardiotoxicity. Neutropenia (especially when given with chemotherapy).
Reviews
Clear filtersThere are no reviews yet.